Vir Biotechnology Inc (VIR) - Final Profit

VIR (Vir Biotechnology Inc) - company brandmark

Vir Biotechnology, Inc. (VIR) acts as an innovator in treating infections, utilizing a unique antibody discovery system to combat influenza and hepatitis. The business strategy relies on developing vaccines capable of fully curing patients. Growth is driven by FDA support and alliances with industry behemoths, while profit stands at -0.25. The quotes provided below on GURU.Markets confirm the resilience of this fundamental model.

VIR: Vir Biotechnology, Inc. Net Profit 07/04/2022 - 10/31/2026

Comprehensive metric breakdowns and analytics for Vir Biotechnology (VIR)

- market value and analyst target forecast:
Stock Price Vir Corp|VIR - Consensus Target
- market capitalization indicators:
Market Value Vir Corp|VIR - Real Price to Acquire Entire Company
- business book valuation details:
Net Assets per Single Share Vir Biotechnology|VIR - Book Capitalization|Market Capitalization to Book Value vir.bio|VIR - Aggregate Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Vir Biotechnology, Inc.|VIR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Vir Biotechnology Inc|VIR - Company Debts|Debts to Net Assets Vir Corp|VIR - Company Long-Term Liabilities|Company Short-Term Debt Vir Biotechnology|Interim Coverage Ratio vir.bio
- earnings and valuation multiples information:
VIR - Company Net Income
Basic company analysis:VIR - Vir Corp
Manufactured products of Vir Biotechnology

A fundamental valuation of Vir Biotechnology, Inc. (VIR) using earnings multiples allows for the determination of the asset's fair value amid high volatility. The company's aggregate profit reflects the net financial result after deducting all operating expenses and taxes. The trend of this indicator demonstrates the effectiveness of the business model's adaptation to macroeconomic shifts. For the biotechnology sector, earnings growth confirms the commercial value of patented antibodies, where success depends directly on the clinical efficacy of drugs during trial stages.

Key competitors

Gilead Corp (GILD) - Net Profit|Net Income CDTX|NVAX: Final Profit|Net Income CVAC (CureVac)|Company Net Income VALN (Valneva Corp)|Net Profit SIGA (SIGA Corp)|Net Financial Result Emergent Bio (EBS)|AVIR - Company Net Income|Final Profit IVVD (Invivyd, Inc.)|ENTA (Enanta Pharmaceuticals, Inc.) - Net Income|Inovio Pharmaceuticals, Inc. (INO) - Net Profit|Company Net Income HilleVax Corp|Kalaris Tx (KLRS) - Net Financial Result|Net Income DYAI (Dyadic International)|Company Net Income NNVC (nanoviricides.com)|Net Profit TLPH (Talphera)|Net Financial Result Cocrystal Pharma Inc (COCP)|TRAW - Company Net Income|Final Profit DWTX (Dogwood Therapeutics, Inc.)|QLGN (Qualigen Therapeutics) - Net Income|AlloVir - Final Profit|VBIV (VBI Vaccines, Inc.) - Net Profit|Company Net Income VIRI|Net Profit VXRT